Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura

Purpura, Schoenlein-Henoch Clinical Trial

Official title:

Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01104428
• Other study ID #: zhangjun555678
• Status: Recruiting
• Phase: Phase 2
• First received: January 25, 2010
• Last updated: September 7, 2010
• Start date: November 2009

Study information

• Verified date: September 2010
• Source: Liaoning University of Traditional Chinese Medicine
• Contact: zhang shaoqing, Master
• Phone: 86-024-86291599
• Email: yanzi8164[@]163.com
• Is FDA regulated: No
• Health authority: China:State Administration of Trditional Chinese Medicine of the People's Republic of China
• Study type: Interventional

Clinical Trial Summary

Due to high incidence of renal damage by Hench-schonlein Purpura(HSP) is the key to affect prognosis, this project moves the research emphasis forward in line with the idea of "prevention of progress of disease", Which concerns on Traditional Chinese Medicine(TCM) clinical research scheme evaluation of HSP, evaluates the renal damage and disease recurrence as the end event, and comes to the evaluation through the comparative study that the vantage point of the scheme of syndrome differentiation and treatment in detoxification, cooling blood and removing blood stasis to the conventional treatments can reduce kidney damage and recurrence rate.

Description:

Target：Optimize the TCM scheme of syndrome differentiation and treatment of HSP in line with the idea of blood- Cooling - Toxin - Removing - Stasis - Dispersing under the path of combination between disease differentiation and syndrome differentiation, and regards reducing the rate of the recurrence of HSP and kidney damage as the end point of evaluation indexes, to evaluate the clinical efficacy of the scheme scientifically. Main research contents: Retrospective case investigation, analysis and research on literature, research on clinical assessment of the scheme of syndrome differentiation and treatment. Methods：With a series of compounds as the main interference factors, choosing the sample estimation of superiority design and adopting the test methods of randomized, double-blind, placebo-controlled to carry out the research of multicenter clinical efficacy evaluation.

It summarizes the advantages and rules of syndrome differentiation and treatment in TCM by means of the comparative study, which provides technical guidelines for the industry and sets an example to summarize the key common technology of clinical research, and also improves the evaluation level of TCM clinical research and efficacy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 256
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 5 Years to 18 Years

Eligibility

Inclusion Criteria:

• To comply with the diagnostic standard of purpura in TCM and Hench-schonlein purpura in western medicine;

• To comply with the diagnostic standard of TCM syndrome differentiation;

• Age between 5 and 18;

• without similar herbal treatment a week before being included;

• Informed Consent Form is required to be singed.

Exclusion Criteria:

• Fall short of the diagnostic standard of purpura in TCM and Hench-schonlein purpura in western medicine;

• Fall short of the diagnostic standard of TCM syndrome differentiation;

• Older then 18 years or younger then 5years;

• Take similar herbal treatment within a week before being included;

• Can not take the drug according to the regulation or follow-up on time

• Patients combine serious primary disease in respiratory?gastrointestinal?hemopoietic?renal,or psychosis,or pestilence;

• Allergic to drugs of this research or others;

• human subject of other clinical research in the nearly tow weeks.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Purpura
• Purpura, Schoenlein-Henoch

Intervention

Drug:
• Placebo
granules, <10years,10g,Three times a day,take orally >10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
• "ziying" granules
granules, <10years,10g,Three times a day,take orally >10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods

Locations

Country	Name	City	State
China	Zhangjun	Shenyang	Liaoning

Sponsors (4)

Lead Sponsor	Collaborator
Liaoning University of Traditional Chinese Medicine	Dalian Children's Hospital, Dongzhimen Hospital, Beijing, Shenyang Hospital of Integrated Traditional and westen Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	whether endpoint such as renal damage or disease recurrence appears in the participants.	Endpoint is a mark of termination or completion. In this clinical research, the renal damage and disease recurrence that constitutes the target outcomes of the trial.	6 months	No
Secondary	whether the TCM syndrome of participants disappears after treatment.	Optimize the TCM scheme of syndrome differentiation and treatment of HSP in line with the idea of blood- Cooling - Toxin - Removing - Stasis - Dispersing, under the path of combination between disease differentiation and syndrome differentiation In the process of disease of a series of function, metabolism and morphological structure changes caused by the subjective feeling of abnormal patient as symptoms.	1 month	No